Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE IN ABSORBASE versus RAYOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE IN ABSORBASE versus RAYOS.
HYDROCORTISONE IN ABSORBASE vs RAYOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist that modulates gene expression, leading to anti-inflammatory, immunosuppressive, and vasoconstrictive effects.
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and metabolic effects; binds to glucocorticoid receptor, modulating gene expression and inhibiting phospholipase A2, cytokine production, and immune cell activity.
Topical: Apply a thin layer to affected area 2-4 times daily.
Initial adult dose 5-60 mg orally once daily, adjusted based on disease severity and response. Typically administered as a single dose in the morning with food.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (plasma cortisol); biological half-life (duration of action) 8-12 hours due to intracellular receptor effects.
2-3 hours (terminal); prolonged in hepatic impairment; circadian-timed formulation intended for once-daily morning dosing.
Renal: primarily as 17-hydroxycorticosteroids and 17-ketosteroids; <5% unchanged. Biliary/fecal: minimal. Metabolites conjugated with glucuronide or sulfate.
Renal: ~80% as inactive metabolites; fecal: ~5%; biliary: small amount.
Category D/X
Category C
Corticosteroid
Corticosteroid